Literature DB >> 187926

4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain.

U Schwabe, M Miyake, Y Ohga, J W Daly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 187926

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN： 0026-895X            Impact factor:   4.436


× No keyword cloud information.
  59 in total

1.  IGF-I-induced differentiation of L6 myogenic cells requires the activity of cAMP-phosphodiesterase.

Authors:  Vania De Arcangelis; Dario Coletti; Marco Conti; Michel Lagarde; Mario Molinaro; Sergio Adamo; Georges Nemoz; Fabio Naro
Journal:  Mol Biol Cell       Date:  2003-04       Impact factor: 4.138

Review 2.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Central hypotensive effects of imidazole acetic acid and rolipram (ZK 62 711) in rats [proceedings].

Authors:  H Karppanen; P Paakkari; A L Orma; I Paakkari
Journal:  Agents Actions       Date:  1979-04

4.  Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP.

Authors:  J Puurunen; C Lücke; U Schwabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-08       Impact factor: 3.000

5.  Effects of chronic treatment with a cyclic AMP-selective phosphodiesterase inhibitor, rolipram, on excitatory amino acid neurotransmission systems in young and aged rat brains.

Authors:  H Kato; T Araki; T Chen; X H Liu; T Hiranuma; K Murase; Y Itoyama; K Kogure
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  Evidence that the presynaptic A2a-adenosine receptor of the rat motor nerve endings is positively coupled to adenylate cyclase.

Authors:  P Correia-de-Sá; J A Ribeiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

7.  Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.

Authors:  D E Griswold; E F Webb; J Breton; J R White; P J Marshall; T J Torphy
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

8.  Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.

Authors:  M Holbrook; N Gozzard; T James; G Higgs; B Hughes
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 10.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.